Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press26610.17650/1994-4098-2010-0-4-33-39MAMMOLOGY. NEW TECHNOLOGIESМАММОЛОГИЯ. НОВЫЕ ТЕХНОЛОГИИThe status of epidermal growth factor receptor and topoisomerase IIα genes in triple-negative breast cancer cellsСтатус генов рецептора эпидермального фактора роста и топоизомеразы IIα в клетках тройного негативного рака молочной железыKarseladzeD. A.КарселадзеД. А.
Russian Federation
dima_karseladze@mail.ruPoddubnayaI. V.ПоддубнаяИ. В.
Russian Federation
KarseladzeA. I.КарселадзеА. И.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМНDepartment of Oncology, Russian Medical Academy of Postgraduate Education, Russian Agency for Health CareКафедра онкологии ГОУ ДПО РМАПО РосздраваDepartment for Pathological Anatomy of Human Tumors, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтдел патологической анатомии опухолей человека ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва291120104333929082014290820142010https://ojrs.abvpress.ru/ojrs/article/view/266

The paper gives the results of studying the genes of epidermal growth factor receptor (EGFR) and topoisomerase IIα (TOP IIα) in patients with triple-negative breast cancer (BC). It is suggested that the lack of EGFR gene amplification might serve as a factor of good prognosis. TOP IIα gene amplification usually occurs in the tumors responsive to chemotherapy including anthracycline drugs. The altered status of the above genes should be interpreted in the context of aneusomy of chromosomes 7 and 17, on which they are located. No association was found between the pattern of EGFR and TOP IIα gene abnormalities and the basaloid phenotype of BC.

Приведены результаты изучения генов рецептора эпидермального фактора роста (EGFR) и топоизомеразы IIα (ТОП IIα) у больных тройным негативным раком молочной железы (РМЖ). Выдвинуто предположение о том, что отсутствие амплификации гена EGFR может служить фактором благоприятного прогноза. Амплификация гена ТОП IIα обычно встречается в опухолях, проявляющих чувствительность к химиотерапии с включением препаратов антрациклинового ряда. Изменение статуса указанных генов следует интерпретировать в контексте анеусомии хромосом 7 и 17, на которых они расположены. Не выявлено взаимосвязи между характером нарушений генов EGFR и ТОП IIα и базалоидным фенотипом РМЖ.

triple-negative breast cancertopoisomerase IIαepidermal growth factor receptoraneusomy of chromosomes 7 and 17тройной негативный рак молочной железытопоизомераза IIαрецептор эпидермального фактора ростаанеусомия хромосом 7 и 171. Sotiriou C., Neo S.Y., McShane L.M. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100(18):10393–8.Sotiriou C., Neo S.Y., McShane L.M. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100(18):10393–8.2. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008;52(1):108–18.Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008;52(1):108–18.3. Bhargava R., Gerald W.L., Li A.R. et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and Her-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18(8):1027–33.Bhargava R., Gerald W.L., Li A.R. et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and Her-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18(8):1027–33.4. Kersting C., Tidow N., Schmidt H. et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84(5):582–7.Kersting C., Tidow N., Schmidt H. et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84(5):582–7.5. Nicholson S., Richard J., Sainsbury C. et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991;63(1):146–50.Nicholson S., Richard J., Sainsbury C. et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991;63(1):146–50.6. Buchholz T.A., Tu X., Ang K.K. et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005;104(4):676–81.Buchholz T.A., Tu X., Ang K.K. et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005;104(4):676–81.7. Collins L.C., Martyniak A.J., Kandel M.J. et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple- negative breast cancers. Am J Surg Pathol 2009;33(7):1093–7.Collins L.C., Martyniak A.J., Kandel M.J. et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple- negative breast cancers. Am J Surg Pathol 2009;33(7):1093–7.8. Kobayashi S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 2008;15(2):153–8.Kobayashi S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 2008;15(2):153–8.9. Oliveras-Ferraros C., Vazquez-Martin A., López-Bonet E. et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple- negative/basal-like breast cancer. Int J Oncol 2008;33(6):1165–76.Oliveras-Ferraros C., Vazquez-Martin A., López-Bonet E. et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple- negative/basal-like breast cancer. Int J Oncol 2008;33(6):1165–76.10. Sasa M., Bando Y., Takahashi M. et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008;97(1):30–4.Sasa M., Bando Y., Takahashi M. et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008;97(1):30–4.11. Viale G., Rotmensz N., Maisonneuve P. et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009;116(2):317–28.Viale G., Rotmensz N., Maisonneuve P. et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009;116(2):317–28.12. Tischkowitz M., Brunet J.C., Begin R.L. et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 2007;7:134.Tischkowitz M., Brunet J.C., Begin R.L. et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 2007;7:134.13. Durbecq V., Di Leo A., Cardoso F. et al. Comparison of topoisomerase-II alpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77(3):199–204.Durbecq V., Di Leo A., Cardoso F. et al. Comparison of topoisomerase-II alpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77(3):199–204.14. Järvinen T.A., Liu E.T. Topoisomerase II alpha gene (TOP2α) amplification and deletion in cancer – more common than anticipated. Cytopathology 2003;14(6):309–13.Järvinen T.A., Liu E.T. Topoisomerase II alpha gene (TOP2α) amplification and deletion in cancer – more common than anticipated. Cytopathology 2003;14(6):309–13.15. Park K., Han S., Gwak G.H. et al. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 2006;98(3):337–42.Park K., Han S., Gwak G.H. et al. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 2006;98(3):337–42.16.Usha L., Tabesh B., Morrison L.E. et al. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2- amplified breast cancer: a retrospective study of paraffin-embedded tumor specimensUsha L., Tabesh B., Morrison L.E. et al. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2- amplified breast cancer: a retrospective study of paraffin-embedded tumor specimensand medical charts. J Hematol Oncol 2008;14;1:12.17. Nielsen K.V., Ejlertsen B., Müller S. et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 2008;47(4):725–34.Nielsen K.V., Ejlertsen B., Müller S. et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 2008;47(4):725–34.18. Nielsen K.V., Müller S., Ejlertsen B. et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol 2010;4(2);161–8.Nielsen K.V., Müller S., Ejlertsen B. et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol 2010;4(2);161–8.19. Rody A., Karn T., Ruckhäberle E. et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009;113(3):457–66.Rody A., Karn T., Ruckhäberle E. et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009;113(3):457–66.20. Sparano J.A., Goldstein L.J., Childs B.H. et al. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 2009;15(24):7693–700.Sparano J.A., Goldstein L.J., Childs B.H. et al. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 2009;15(24):7693–700.21. O'Malley F.P., Chia S., Tu D. et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101(9):644–50.O'Malley F.P., Chia S., Tu D. et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101(9):644–50.22. Mueller R.E., Parkes R.K., Andrulis I., O'Malley F.P. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39(4):288–97.Mueller R.E., Parkes R.K., Andrulis I., O'Malley F.P. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39(4):288–97.23. Карселадзе А.И. Реакция флуоресцентной гибридизации в диагностике онкологических заболеваний. М., 2009; с. 31–3.Карселадзе А.И. Реакция флуоресцентной гибридизации в диагностике онкологических заболеваний. М., 2009; с. 31–3.24. Mendelin J., Grayson M., Wallis T., Visscher D.W. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. Lab Invest 1999;79(4):387–93.Mendelin J., Grayson M., Wallis T., Visscher D.W. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. Lab Invest 1999;79(4):387–93.25. Yeh I.T., Martin M.A., Robetorye R.S. et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009;22(9):1169–75.Yeh I.T., Martin M.A., Robetorye R.S. et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009;22(9):1169–75.